Stage III or IVA endometrial cancer carries a significant risk of systemic and loco regional recurrence.
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T h e ne w e ngl a nd jou r na l o f m e dicine W omen with locally advanced (International Federation of Gynecology and Obstetrics [FIGO] stage III or IVA) endometrial carcinoma are a heterogeneous group of patients who are at risk for both local and systemic disease recurrence. Clinical and patho logic factors affecting the risk of recurrence in clude the extent of abdominal and pelvic disease, histologic subtype, nodal involvement, presence of extranodal disease, and the completeness of surgical resection. 14 Because of the heterogeneity of this patient population, a wide range of 5year survival estimates has been reported, and an ap propriate postsurgery strategy remains unclear. 58 Pelvic or whole abdominal radiotherapy has traditionally followed surgical resection. 6, 8 This approach prevented pelvic recurrence but was less effective in preventing systemic recurrence, which limited longterm survival. In a randomized trial conducted by the Gynecologic Oncology Group (GOG), GOG 122, chemotherapy was found to be superior to radiotherapy in treating locally advanced disease, and it thus became part of the standard treatment. 9 However, if chemotherapy is given alone, the incidence of locoregional re currence approaches 20%, 9 heralding subsequent distant metastasis and death. Therefore, it was logical to hypothesize that an approach that com bined the methods of treatment would improve outcomes by preventing local (pelvic) and distant recurrences.
This combined approach has been studied, but its efficacy relative to that of chemotherapy alone is not known. Patients with stage III endo metrial carcinoma treated with chemoradiother apy in the Radiation Therapy Oncology Group (RTOG) protocol 9708 trial had an estimated 4year overall survival of 77% and relapsefree survival of 72%. 10 In the GOG 184 trial, which compared two chemotherapy regimens after tu mor volume-directed externalbeam radiotherapy, the 3year relapsefree survival estimates were 62% to 64%. 11 These results supported the fea sibility and efficacy of a combined treatment strategy.
The purpose of the current trial (GOG 258) was to evaluate the use of concurrent tumor volume-directed externalbeam radiation ther apy and chemotherapy (i.e., chemoradiotherapy) as compared with the use of chemotherapy alone. 9,1113 Here, we report on relapsefree sur vival, the primary end point.
Me thods

Patients and Trial Oversight
We enrolled women who were 18 years of age or older and who had surgical stage III or IVA en dometrial carcinoma according to FIGO 2009 staging criteria of any histologic subtype or had FIGO 2009 surgical stage I or II clearcell or serous endometrial carcinoma and peritoneal washings that were positive for cancer cells. Hysterectomy and bilateral salpingooophorec tomy had to have been performed within 8 weeks before trial entry. No single residual tumor mass could be larger than 2 cm in greatest dimension. Pelvic and paraaortic lymphnode biopsy or dis section was optional. Normal organ function and a GOG performance status score of 2 or lower were required (scores range from 0 to 5, with higher scores reflecting greater disability). Patients with carcinosarcoma or recurrent endo metrial carcinoma were excluded.
The trial was conducted in accordance with applicable regulatory requirements and the prin ciples of the Declaration of Helsinki. Approval for the trial and for the informedconsent process from a local or central institutional review board or independent ethics committee was required for site participation. Patients provided written informed consent before enrollment.
Trial Design and End Points
This randomized, multicenter, phase 3 trial was designed with input from the Gynecologic Oncol ogy Group. The authors vouch for the accuracy and completeness of the data and for the fidelity of the trial to the protocol, available with the full text of this article at NEJM.org. The trial treatments were paid for by medical insurance, and the trial was supported by the National Can cer Institute. All the patients were registered through the National Cancer Institute Oncology Patient Enrollment Network. Treatment was ran domly assigned at the GOG Statistical and Data Center and was concealed until registration with verification of eligibility. Randomization was stratified according to age and the presence or absence of gross residual disease. The primary objective was to determine whether chemoradio therapy would be associated with a lower incidence of recurrence or death (i.e., longer relapsefree survival) than chemotherapy alone. Secondary ob jectives were betweengroup comparisons of over all survival, the incidence and severity of acute and late toxic effects, and patientreported qual ity of life.
Treatment and Assessments
The two treatment regimens were randomly as signed in a 1:1 ratio within permuted blocks. The chemoradiotherapy regimen consisted of cis platin at a dose of 50 mg per square meter of bodysurface area given intravenously on days 1 and 29 together with volumedirected externalbeam radiation therapy, followed by carboplatin given at a dose to achieve an area under the concentra tion-time curve (AUC) of 5 to 6 plus paclitaxel at a dose of 175 mg per square meter every 21 days for four cycles, with granulocyte colonystimu lating factor (GCSF) support. The chemotherapy only regimen consisted of carboplatin (to achieve an AUC of 6) plus paclitaxel at a dose of 175 mg per square meter every 21 days for six cycles. In the chemoradiotherapy group, externalbeam ra diation therapy was delivered to the pelvis with or without paraaortic fields. The planned total dose was 4500 cGy in 25 fractions at 180 cGy per fraction. Intensitymodulated radiotherapy and vaginal brachytherapy were allowed only in the chemoradiotherapy group. Disease assessments included computed tomography (CT) of the ab domen and pelvis and chest radiography at base line, the end of treatment, every 6 months for the first 2 years, and then annually up to 5 years. Safety assessments included recording of adverse events and concomitant medications, physical ex amination, and hematologic and chemical testing on the same schedule. Adverse events were grad ed with the use of the Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Annual followup was planned beyond 5 years.
The Trial Outcome Index of the Functional Assessment of Cancer Therapy (FACT) for endo metrial cancer (FACTEn) and the FACT/GOGneurotoxicity (NTX) subscale were used to mea sure quality of life and chemotherapyinduced neurotoxic effects (see the Supplementary Appen dix, available at NEJM.org). Two items from the FACT for colorectal cancer (FACTC) combined with four items from the FACTEn Trial Outcome Index were used to assess gastrointestinal symp toms. Each item in the FACTEn Trial Outcome Index and the FACT/GOGNTX subscale was scored with the use of a 5point scale (0, not at all; 1, a little bit; 2, somewhat; 3, quite a bit; 4, very much). The total FACTEn Trial Outcome Index score was calculated as the sum of the subscale scores if more than 80% of the items were an swered within each subscale. The total scores range from 0 to 120 for the FACTEn Trial Outcome Index and from 0 to 16 for the FACT/GOGNTX subscale (see the Supplementary Appendix). A higher Trial Outcome Index, NTX, or gastrointes tinal score suggests better quality of life or fewer symptoms. The minimally clinically important dif ference is 6 points for the FACTEn Trial Outcome Index and 1.2 points for the FACT/GOGNTX subscale. 14 Assessments were completed before treatment (at baseline), 1 week after completing radiation therapy or before cycle 3 of chemo therapy, and 18 and 70 weeks after the start of treatment.
Quality Assurance
The trial was open to enrollment between June 29, 2009, and July 28, 2014, and the data cutoff for analysis was March 9, 2017. The GOG Pathol ogy Committee verified histologic subtypes, grades, and stages for all patients. Eligibility, surgery, and radiation plans were reviewed centrally. The trial chairs monitored eligibility, chemotherapy delivery and modifications, adverse events, and radiographic assessments.
Statistical Analysis
The null hypothesis was that chemoradiotherapy would not achieve higher relapsefree survival percentages than chemotherapy alone. A 28.5% lower incidence of recurrence or death (relative hazard, 1.4, corresponding to relapsefree sur vival at 3 years of 61% in the chemotherapyonly group and 70% in the chemoradiotherapy group) was considered clinically significant. Observation of at least 252 recurrences or death events was needed to attain 85% statistical power with type I error for a onetailed comparison at 0.05 for relapsefree and overall survival separately. Under the assumption of a decrease in the hazard of recurrence or death over time, a sample size of 804 was targeted. Independence between relapse free or overall survival and the randomly assigned treatment was assessed with a stratified logrank test in an intentiontotreat analysis including the eligible patients. Two interim analyses were planned when 42% (105) and 83% (210) of the expected number of recurrences or deaths had been reported. These were reported to the data and safety monitoring board in September 2013 and January 2016. No action was taken to alter the conduct of the trial on the basis of those interim analyses. A Kruskal-Wallis test correct ed for ties was used to compare the maximum grade of acute and late adverse effects of therapy (see the Supplementary Appendix). Between group differences in qualityoflife scores were assessed with a linear mixed model with adjust ment for the pretreatment score, assessment time point, and age at enrollment.
R esult s
Patients and Follow-up
Enrollment concluded with 813 patients; 77 were deemed ineligible, most commonly because of an inappropriate cancer stage or a lack of patho logical documentation. In addition, 29 eligible patients were never treated, with 24 of those hav ing been assigned to the chemoradiotherapy group. At the time of this report, all patients were no longer receiving the trial treatment and, after treat ment, 25 women had withdrawn consent for con tinued followup (12 in the chemoradiotherapy group and 13 in the chemotherapyonly group) ( Fig. S1 in the Supplementary Appendix). There were 51 major protocol violations in 399 reviewed cases: 43 in the chemoradiotherapy group and 8 in the chemotherapyonly group; 15 in the chemo radiotherapy group were related to radiation de livery (see the Supplementary Appendix).
The median followup duration was 47 months; 295 recurrence or death events were reported in the entire study population, and 271 were report ed among eligible patients. The safety analysis in cluded all eligible and treated patients, whereas the efficacy analysis included all eligible patients, regardless of whether they received treatment.
Characteristics of the patient and the tumors are shown in Table 1 . A total of 72% of patients were between 50 and 69 years of age (median age, 60 years), 90% identified as nonHispanic, and 77% identified as white. The performance status score was 0 for 74% of enrolled patients, and the endometrioid histologic type was predominant. Stratification factors were balanced between the treatment groups, with nearly 98% of patients having no gross residual disease. Surgery to re move lymph nodes was reported in more than 94% of patients, with a median number of 13 pelvic nodes and 3 paraaortic nodes removed.
Treatment
Overall, 75% of patients completed all prescribed chemoradiotherapy in a median period of 21 weeks. * There were no significant differences in baseline characteristics between the treatment groups. Percentages may not total 100 because of rounding. † Race was reported by the patient. ‡ A Gynecologic Oncology Group (GOG) performance status score of 2 or lower was required for enrollment (scores range from 0 to 5, with higher scores reflecting greater disability). § Stages were assigned according to the International Federation of Gynecology and Obstetrics (FIGO) 2009 classification; stages range from I to IV, with higher stages indicating more advanced spread of cancer. ¶ Body-mass index (BMI) is the weight in kilograms divided by the square of the height in meters. The majority of patients in the chemoradiother apy group received 45 cGy, intensitymodulated radiotherapy was used in 30% of cases, and 201 patients received vaginalcuff brachytherapy. Two cycles of cisplatin were coadministered with radia tion to more than 85% of patients in the chemo radiotherapy group, and 75% of the patients in that group received all four planned cycles of carboplatin and paclitaxel. In the chemotherapy only group, 85% of women received all six cycles during a median period of 17 weeks ( Table S1 in the Supplementary Appendix). Two patients in the chemotherapyonly group received additional che motherapy and radiotherapy before progression; both patients discontinued the trial treatment early because of toxic effects. Between 8 and 10% of patients discontinued treatment due to adverse events. Therefore, the null hypothesis that chemoradio therapy is not superior to chemotherapy alone could not be rejected (P = 0.20 by onetailed test) ( Fig. 1) . A sensitivity analysis indicated that the results observed in the eligible treated popula tion were consistent with the results among all eligible patients. A total of 165 deaths have been reported to date -86 in the chemoradiotherapy group and 79 in the chemotherapyonly group. Of those deaths, 73% and 81%, respectively, were due to endometrial cancer progression. The data on over all survival are not sufficiently mature to allow comparison between the groups. Exploratory sub group analyses of relapsefree survival did not identify a subgroup of patients who may have benefited more from chemoradiotherapy than from chemotherapy alone, when age, histologic subtype, surgical stage, bodymass index, and the presence or absence of gross residual disease were taken into consideration (Fig. 2) . The cumu lative incidence of vaginal disease recurrence at 60 months of followup was 2% in the chemora diotherapy group and 7% in the chemotherapy only group (hazard ratio, 0.36; 95% CI, 0.16 to 0.82) (Fig. 3A) . The cumulative incidence of pel vic or paraaortic node recurrence at 60 months was 11% in the chemoradiotherapy group and 20% in the chemotherapyonly group (hazard ratio, 0.43; 95% CI, 0.28 to 0.66) (Fig. 3B) . The cumulative incidence of distant recurrence at 60 months was 27% in the chemoradiotherapy group and 21% in the chemotherapyonly group (hazard ratio, 1.36; 95% CI, 1.00 to 1.86) (Fig. 3C) . Coincident local and distant recur rences at first presentation were found in 2.2% of patients in the chemoradiotherapy group and in 4.9% of patients in the chemotherapyonly group; the sites of initial recurrence are shown in Table S3 in the Supplementary Appendix.
Toxicity
Quality of Life
Adherence to the qualityoflife assessments was 95% at baseline, 90% at 6 weeks, 87% at 18 weeks, and 78% at 70 weeks. The patients who could be evaluated were those with a valid base line assessment and at least one followup assess ment (332 in the chemoradiotherapy group and 349 in the chemotherapyonly group). After ad justment for age and baseline scores, the least squares mean Trial Outcome Index score at 18 weeks in the chemoradiotherapy group was 5.2 points lower (97.5% CI, 2.7 to 7.8) than that in the chemotherapyonly group. The difference in this score remained significant at 70 weeks (3.4 points lower in the chemoradiotherapy group; 97.5% CI, 0.7 to 6.2) but did not exceed the 6point difference that had been preset as clini cally meaningful. 14 Patients in both groups re ported symptoms of neurotoxicity in associa tion with treatment, but the leastsquares mean FACT/GOGNTX subscale score at 6 weeks among patients receiving chemotherapy only was 2.0 points lower (97.5% CI, 1.4 to 2.6) than that in the chemoradiotherapy group (i.e., reflecting worse symptoms in the chemotherapyonly group), whereas patients receiving chemoradiotherapy re ported gastrointestinal symptoms at both 6 weeks and 18 weeks that were significantly worse than those in the chemotherapyonly group.
Discussion
The role of radiotherapy in local control of endo metrial carcinoma has been firmly established 1518 ; however, externalbeam radiotherapy does not significantly improve overall survival in patients with earlystage, lowerrisk disease. This was shown in both the Post Operative Radiation Therapy in Endometrial Carcinoma (PORTEC) 1 trial and the GOG 99 trial, 17, 19 and its use in this context remains tailored to women who are con sidered to be at high risk for relapse. 20 Because the risk of local relapse is higher among women with stage III uterine cancer than among those with earlystage disease, 21 whole abdominal or pelvic radiotherapy has traditionally been incor porated in the standard postoperative approach for those with stage III disease. 6,22 However, given the competing risk of distant metastasis, which has led to the implementation of chemotherapy as the standard of care, 9 the role of radiotherapy remains uncertain. This trial prospectively eval uated the effect of combined chemotherapy plus radiotherapy in patients with stage III or IVA endometrial carcinoma as compared with the effect of chemotherapy alone. The results show that the combined regimen was not superior to chemotherapy alone in prolonging relapsefree survival, although locoregional relapses were less frequent than with chemotherapy alone. An important strength of this trial is the rig orous definition of the patient population, which includes only patients with adnexal, lymphnode, and pelvic, nonperitoneal metastasis. With the revision of the FIGO staging system in 2009, 23 the trial was amended to exclude patients with peritoneal washings that were positive for cancer cells but with no evidence of extrauterine endo metrioid tumor, because such patients have bet ter outcomes than other patients with stage III disease. 24, 25 One exception was the group of pa tients with positive peritoneal washings and car cinoma of the clearcell or serous histologic type, who are recognized as having a high risk of re currence 2630 ; these patients were included in this trial and represented less than 3% of the trial population. Nearly 75% of the patient population had endometrial carcinoma with lymphnode in volvement. Although surgical staging was not mandated, the majority of patients underwent full staging procedures.
Chemotherapy became the mainstay of treat ment for highrisk endometrial carcinoma after it became clear that distant metastasis is a key determinant of survival in patients with locally advanced endometrial carcinoma. In the GOG 122 trial, overall survival at 60 months was 10 per centage points higher among patients who received doxorubicin and platinum than among those treated with whole abdominal radiotherapy. 9 The role of chemotherapy has been studied by other groups. 5,3133 Maggi et al. reported no significant difference in overall survival between patients who received cyclophosphamide, doxorubicin, and cisplatin (CAP) and those who received external beam radiotherapy. 31 In the Japanese Gyneco logic Oncology Group trial, which involved pa tients with highrisk endometrial carcinoma, the percentages of patients surviving without pro gression (83% vs. 66%) and surviving overall (89% vs. 73%) were significantly higher among those who were randomly assigned to receive CAP than among those who received pelvic exter nalbeam radiotherapy. 32 In a pooled analysis of trials conducted by the Nordic Society of Gyne cological Oncology (NSGO)-European Organi zation for Research and Treatment of Cancer (EORTC) and the Mario Negri Gynecologic On cology (MaNGO) group, sequential chemotherapy and pelvic externalbeam radiotherapy approached statistical superiority to pelvic radiotherapy alone (hazard ratio, 0.69; P = 0.07). 33 Adjuvant chemo radiotherapy was compared with externalbeam radiotherapy in patients with earlystage high risk and stage III endometrial carcinoma in the recently reported PORTEC 3 trial. Overall sur vival was not affected by the addition of chemo therapy, but the combined regimen improved relapsefree survival relative to radiotherapy (75% vs. 68%), with most of the benefit found in pa tients with stage III disease. 34 Several regimens have been tested in patients with locally advanced or metastatic endometrial carcinoma, including those regimens named above, paclitaxel-doxorubicin-cisplatin, and carbo platin-paclitaxel. 11, 13, 31, 33, 35 Because carboplatinpaclitaxel induced similar outcomes with less toxicity, 12 this regimen was adopted in clinical practice and in this trial. More than 85% of pa tients in this trial who were in the chemotherapy only group received the planned six cycles, whereas only 63% completed all cycles of treat ment in GOG 122, as a result of treatmentrelated toxic effects. Full delivery of chemotherapy was diminished by the addition of radiotherapy, with only 75% of women completing the four planned courses in the chemoradiotherapy group. These results are similar to previous observations in GOG 184, in which only 80% of patients com pleted the intended chemotherapy after radio therapy, 11 and may have contributed to the higher thananticipated frequency of distant metastases.
The results of our trial could lead to specula tion that externalbeam radiotherapy should be delivered after completion of chemotherapy. Single institution retrospective studies using a "sand wich" radiotherapy-chemotherapy approach have suggested a reasonable sideeffect profile and estimated 5year overall and distant metastasis free survival of 77% and 85%, respectively. 36, 37 Because these results have not been validated prospectively, they should not be adopted with out further study. Likewise, substituting vaginal brachytherapy for externalbeam radiotherapy may be tempting, but because the risk of vaginal recur rence is low, intracavitary radiotherapy should be reserved for women who are at high risk for vaginal relapse. Finally, the shortterm and long term effects of treatment on quality of life should be considered. Although acute toxic effects were more common in the chemoradiotherapy group than in the chemotherapyonly group in our trial, most were lowgrade and reversible on treatment discontinuation. Chronic toxic effects included diarrhea, lymphedema, and musculoskeletal events and were more common with chemoradiother apy, which affected patientreported outcomes. Late second cancers are also a risk.
In summary, in this randomized trial, the combined regimen of chemotherapy plus radia tion did not provide a benefit over chemotherapy alone with respect to relapsefree survival in pa tients with stage III or IVA endometrial carci noma. Our data are compatible with the hypoth esis from previous studies that completion of chemotherapy is important for the prevention of distant relapse.
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